Trials / Completed
CompletedNCT03117621
Observational Study of Blinatumomab
An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 279 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
An observational study of blinatumomab safety and effectiveness, utilisation, and treatment practices.
Detailed description
The primary objective of this study is to characterize the safety of Blincyto in routine clinical practice. Blincyto effectiveness, medication errors, and utilisation; and select healthcare resource use while using Blincyto will also be described. Safety and effectiveness of Blincyto in specified subgroups of patients will also be assessed.
Conditions
Timeline
- Start date
- 2017-03-22
- Primary completion
- 2024-03-20
- Completion
- 2024-03-20
- First posted
- 2017-04-18
- Last updated
- 2025-04-04
Locations
80 sites across 13 countries: Austria, Czechia, Finland, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT03117621. Inclusion in this directory is not an endorsement.